



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Nabil Hanna et al.

Group Art Unit: 1644

Application Serial No. 09/435,992

Examiner: P. Gambel

Filed: November 8, 1999

RECEIVED  
SEP 06 2001  
TECH CENTER 1600/2900

Title: TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN COMBINATION  
WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND RADIOTHERAPY

# 17/A  
yrd  
9/13/01

\* \* \* \* \*

ELECTION

Hon. Commissioner of Patents  
Washington, D.C. 20231

Sir:

In response to the Official Action [Restriction Requirement] dated July 3, 2001,  
Applicants submit the following amendments and remarks.

In the Claims:

Please cancel non-elected Claims 42-56 without prejudice or disclaimer.

Please enter the following new Claims:

--57. The method of Claim 10, wherein the chemotherapeutic agent for treating leukemia is an alkylating agent.

58. The combination therapy of Claim 27, wherein the B-cell leukemia is a chronic B-cell leukemia, acute lymphoblastic leukemia of a B-cell lineage, or chronic lymphocytic leukemia of a B-cell lineage.

59. The combination therapy of Claim 58, wherein the chemotherapeutic agent for treating a B-cell leukemia is selected from the group consisting of cyclophosphamide; CHOP; CMP; CVP; and CAP.--